Darglitazone previously known as CP is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator activated receptor PPAR an orphan member of the nuclear receptor superfamily of transcription factors It has a variety of insulin sensitizing effects such as improving glycemic and lipidemic control and was researched by Pfizer as a treatment of metabolic disorders such as type diabetes mellitus
Its development was terminated on November